↓ Skip to main content

Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)

Overview of attention for article published in this source, August 2010
Altmetric Badge

Mentioned by

3 blogs
1 policy source
1 Facebook page


109 Dimensions

Readers on

105 Mendeley
2 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
Published by
John Wiley & Sons, Ltd, August 2010
DOI 10.1002/14651858.cd004677.pub2
Pubmed ID

Williams, Katrina, Wheeler, Danielle M, Silove, Natalie, Hazell, Philip


Autism spectrum disorders (ASD) are characterised by abnormalities in social interaction and communication skills, as well as stereotypic behaviours and restricted activities and interests. Selective serotonin reuptake inhibitors (SSRIs) are prescribed for the treatment of co-morbidity associated with ASD such as depression, anxiety and obsessive-compulsive behaviours.

Mendeley readers

The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
United Kingdom 1 <1%
Netherlands 1 <1%
Egypt 1 <1%
Unknown 100 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 22 21%
Student > Master 14 13%
Student > Bachelor 13 12%
Student > Doctoral Student 13 12%
Student > Ph. D. Student 12 11%
Other 22 21%
Unknown 9 9%
Readers by discipline Count As %
Medicine and Dentistry 34 32%
Psychology 25 24%
Agricultural and Biological Sciences 8 8%
Nursing and Health Professions 7 7%
Social Sciences 6 6%
Other 15 14%
Unknown 10 10%